Curocell KOSDAQ:A372320 Stock Report

Last Price

₩30.65k

Market Cap

₩432.6b

7D

-3.3%

1Y

-11.0%

Updated

09 Jan, 2025

Data

Company Financials

Curocell Inc.

KOSDAQ:A372320 Stock Report

Market Cap: ₩432.6b

A372320 Stock Overview

Develops CAR-T cell therapy for the treatment of cancer. More details

A372320 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Has not reported any financial data

Volatile share price over the past 3 months compared to the KR market

Shareholders have been diluted in the past year

My Notes

Capture your thoughts, links and company narrative

Curocell Inc. Competitors

EuBiologics

KOSDAQ:A206650

₩480.4b

BioNote

KOSE:A377740

₩522.5b

Bioneer

KOSDAQ:A064550

₩510.5b

Genomictree

KOSDAQ:A228760

₩501.4b

Price History & Performance

Summary of share price highs, lows and changes for Curocell
Historical stock prices
Current Share Price	₩30,650.00
52 Week High	₩43,000.00
52 Week Low	₩19,390.00
Beta	0
1 Month Change	23.84%
3 Month Change	-2.85%
1 Year Change	-11.03%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	41.24%

Recent News & Updates

Recent updates

Shareholder Returns

	A372320	KR Biotechs	KR Market
7D	-3.3%	4.0%	5.2%
1Y	-11.0%	13.2%	-4.3%

Return vs Industry: A372320 underperformed the KR Biotechs industry which returned 12.3% over the past year.

Return vs Market: A372320 underperformed the KR Market which returned -4.2% over the past year.

Price Volatility

Is A372320's price volatile compared to industry and market?
A372320 volatility
A372320 Average Weekly Movement	10.9%
Biotechs Industry Average Movement	8.9%
Market Average Movement	6.7%
10% most volatile stocks in KR Market	12.8%
10% least volatile stocks in KR Market	3.4%

Stable Share Price: A372320's share price has been volatile over the past 3 months compared to the KR market.

Volatility Over Time: A372320's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of KR stocks.

About the Company

Founded	Employees	CEO	Website
2016	n/a	n/a	www.curocellbtx.com

Curocell Inc. develops CAR-T cell therapy for the treatment of cancer. It focuses on the development of CD19 CAR-T for the treatment of lymphoma; and BCMA CAR-T for the treatment of multiple myeloma. The company was incorporated in 2016 and is based in Daejeon, South Korea.

Curocell Inc. Fundamentals Summary

How do Curocell's earnings and revenue compare to its market cap?
A372320 fundamental statistics
Market cap	₩432.57b
Earnings (TTM)	₩0
Revenue (TTM)	n/a

n/a

P/E Ratio

n/a

P/S Ratio

Is A372320 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A372320 income statement (TTM)
Revenue	₩0
Cost of Revenue	₩0
Gross Profit	₩0
Other Expenses	₩0
Earnings	₩0

Last Reported Earnings

n/a

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did A372320 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/09 04:30
End of Day Share Price	2025/01/09 00:00
Earnings	N/A
Annual Earnings	N/A

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Curocell Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution